Arcutis Biotherapeutics, Inc. - Common stock (ARQT) — AI analysis & news
Arcutis Biotherapeutics, Inc. - Common stock (ARQT) stock: 7 recent news items, slightly positive aggregate sentiment, AI analysis and market context on…
Current sentiment read
Across the last 7 indexed ARQT stories, aggregate finance-aware sentiment is slightly positive (+0.16 on a -1 to +1 scale).
Latest ARQT news
- Morgan Stanley initiates Lakefront Biotherapeutics stock with Equalweight rating By Investing.com - Investing.com India · Investing.com India
- Arcutis Biotherapeutics director Welgus sells $127,325 in stock By Investing.com - Investing.com Nigeria · Investing.com Nigeria
- Arcutis Biotherapeutics director Welgus sells $127,325 in stock By Investing.com - Investing.com UK · Investing.com UK
- Arcutis Biotherapeutics stock hits 52-week high at $31.80 By Investing.com - Investing.com India · Investing.com India
- Arcutis Biotherapeutics stock hits 52-week high at $31.80 By Investing.com - Investing.com UK · Investing.com UK
- RBC upgrades Lakefront Biotherapeutics stock rating on autoimmune drug potential - Investing.com India · Investing.com India
- Arcutis Biotherapeutics EVP Matsuda sells $91.8k in shares By Investing.com - Investing.com India · Investing.com India
FAQ
What is the current sentiment for ARQT stock?
Aggregate finance-aware sentiment across the last 7 indexed ARQT news stories is slightly positive (+0.16 on a -1 to +1 scale).